Meunier Mathieu

9PUBLICATIONS
84CO-AUTHORS
Medical infection agents (incl. prions)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMedical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 17, 2026
Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry.

|Aug 01, 2025
Evaluating a predictive model of tyrosine kinase inhibitor therapy failure in a European-type cohort: a step towards population-specific tools.

Sylvain Moinard, Benjamin Lebecque, Tom Lachaise

|Jun 25, 2025
IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score.

Marco G Raddi, Sophie Park, Michaela Fontenay

|Apr 08, 2025
Gut microbiota restoration with oral pooled fecal microbiotherapy after intensive chemotherapy: the phase 1b CIMON trial.

Florent Malard, Sylvain Thepot, Thomas Cluzeau

|Mar 31, 2025
Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid Disorders.

David Fandrei, Jean Pegliasco, Florence Pasquier

|Dec 05, 2022
Lower-risk myelodysplastic syndromes: Current treatment options for anemia.

Mathieu Meunier, Sophie Park

Pageof 2

Frequent Collaborators

2 joint publications

Sophie Park

1 joint publications

Julie Brault

1 joint publications

David Laurin

1 joint publications

Mylène Pezet